The Stark law, which prohibits physician referrals for Medicare services to entities with which they share a financial relationship, is due for an overhaul, according to a report released by Senate Finance Committee Chairman Orrin Hatch, R-Utah.

The Food and Drug Administration has approved several new weight loss interventions in the past year, but one in particular seems to be raising eyebrows among physicians.

Athletes, coaches and staff traveling to Brazil as part of the 2016 Summer Olympics and Paralympics will be monitored by researchers for potential exposure to the Zika virus.

The trade association for brand-name drug manufacturers could soon count the largest generic drug maker among its members—and the brand-name companies aren’t entirely comfortable with the idea.

The risks of “stem cell tourism” might be overplayed, according to a new paper published June 30 in the journal Cell Stem Cell. But only because the real risks of unregulated stem cells might actually be within the U.S. 

Nearly 13 percent of the 12.7 million people who bought coverage on the Affordable Care Act’s health insurance marketplaces for 2016 had dropped out by the end of March.

AstraZeneca’s cholesterol medicine Crestor’s patent protection is set to expire July 8, according to FDA standards, but the company has other plans for the drug. 

The House Energy and Commerce Committee has issued a subpoena to HHS Secretary Sylvia Burwell to turn over documents related to the Affordable Care Act’s reinsurance program, which Republican members on the committee claim has been improperly funded by the agency.